| Radiopharmaceutical |
Method | Support Media | Solvent | Cpd (Rf) |
| Tc-99m DMSA |
ITLC |
ITLC-SA 1 x 8 cm |
Acetone |
DMSA + HR (0.0) FT (1.0) |
| Tc-99m MAG3 |
SepPak |
C-18 Cartridge |
Ethanol (³95%) 0.001N HCl 1:1 EtOH/Saline |
Hydrophilic impurities (0.001N HCl) MAG3 (1:1 EtOH/Saline) SepPak (Non-elutable impurities) |
| Tc-99m Exametazime (Ceretec) |
ITLC |
(1) ITLC-SG 1 x 6 cm (2) ITLC-SG 1 x 6 cm (3) Whatman #1 1 x 6 cm |
(1) MEK (2) Saline (3) 50% Acetonitrile |
(1) 1o + FT (1.0) 2o + HR (0.0) (2) FT (1.0) 1o + 2o + HR (0.0) (2) 1o + 2o + FT (1.0) HR (0.0) |
| Tc-99m Bicisate (Neurolite) |
ITLC |
Baker-flex SG #1BF 2.5 x 7.5 cm |
Ethyl Acetate |
Bicisate (1.0) Impurities (0.0) |
| Tc-99m MAA |
ITLC |
31ET 1 x 8 cm |
Acetone |
FT (1.0) MAA + HR (0.0) |
| Tc-99m Pertechnetate |
ITLC |
ITLC-SG 1x 8 cm |
Acetone |
FT (1.0) HR(0.0) |
| Tc-99m MDP |
ITLC |
(1) 31 ET 1 x 8 cm (2) ITLC-SG 1x 8 cm |
(1) Acetone (2) Water |
(1) FT (1.0) MDP + HR (0.0) (2) MDP + FT (1.0) HR (0.0) |
| Tc-99m PYP |
ITLC |
(1) 31 ET 1 x 8 cm (2) ITLC-SG 1 x 8 cm |
(1) Acetone (2) Water |
(1) FT (1.0) MDP + HR (0.0) (2) MDP + FT (1.0) HR (0.0) |
| Tc-99m Sestamibi (Cardiolite) |
ITLC |
Bakerflex Al2O3 #1BF 2.5 x 7.5 cm |
Ethanol (³95%) |
Sestamibi (1.0) Impurities (0.0) |
| Tc-99m Tetrofosmin (Myoview) |
ITLC |
ITLC-SG 2 x 20 cm |
35:65 v/v Acetone: Dichloromethane |
HR (0.0 - 0.2) Tetrofosmin (0.2 - 0.8) FT (0.8 - 1.0) |
| Ultra-Tag RBC |
Centrifuge |
RBC pellet Supernate |
||
| Tc-99m HSA |
ITLC |
(1) Whatman #1 1 x 8 cm (2) ITLC-SG Pre-saturated with 5% HAS 1 x 8 cm |
(1)Acetone (2) EtOH: NH4OH: Water (2:1:5) |
(1) FT (1.0) H SA + HR (0.0) (2) FT + H SA (1.0) HR (0.0) |
| Tc-99m DTPA |
ITLC |
(1) 31 ET 1 x 8 cm (2) ITLC-SG 1 x 8 cm |
(1) Acetone (2) Water |
(1) FT (1.0) DTPA + HR (0.0) (2) DTPA + FT (1.0) HR (0.0) |
| Tc-99m GH (Gluceptate) |
ITLC |
(1) 31 ET 1 x 8 cm (2) ITLC-SG 1 x 8 cm |
(1) Acetone (2) Water |
(1) FT (1.0) GH + HR (0.0) (2) GH + FT (1.0) HR (0.0) |
| Radiopharmaceutical |
Method |
Support Media |
Solvent | Cpd (Rf) |
| Tc-99m SC (Sulfur Colloid) |
ITLC |
31 ET 1 x 8 cm |
Acetone |
FT (1.0) SC (0.0) |
| Tc-99m DISIDA |
ITLC |
(1) ITLC-SA 1 x 8 cm (2) ITLC-SG 1 x 8 cm |
(1) 20% NaCl (2) Water |
(1) FT (1.0) DISIDA + HR (0.0) (2) DISIDA + FT (1.0) HR (0.0) |
| Tc-99m Mebrofenin |
ITLC |
(1) ITLC-SA 1 x 8 cm (2) ITLC-SG 1 x 8 cm |
(1) 20% NaCl (2) Water |
(1) FT (1.0) Meb + HR (0.0) (2) Meb + FT (1.0) HR (0.0) |
| Tc-99m Apcitide (AcuTect) |
ITLC |
(1) ITLC-SG 2 x 10 cm (2) ITLC-SG 2 x 10 cm |
(1) Sat. NaCl (2) Water |
(1) FT+ GH (0.75 - 1.0) Immobiles+ AcuT (0.0 - 0.75) (2) FT + GH + AcuT (0.25 - 1.0) Immobile (0.0 - 0.25) |
| Tc-99m Depreotide (NeoTect) |
ITLC |
(1) ITLC-SG 2 x 10 cm (2) ITLC-SG 2 x 10 cm |
(1) Sat. NaCl (2) 1:1 v/v MeOH:1M NH4Acetate |
(1) FT + GH + EDTA (0.75 - 1.0) Immobiles + Neo (0.0 - 0.75) (2) FT + GH + EDTA + Neo (0.4 - 1.0) Immobiles (0.0 - 0.4) |
| Tc-99m Arcitumomab (CEA-Scan) |
ITLC |
ITLC-SG 1 x 9 cm |
Acetone |
FT (1.0) CEA (0.0) |
| Tc-99m Nofetumomab (Verluma) |
ITLC |
ITLC-SG 2 x 10 cm |
12% w/v TCA |
FT (0.8 -1.0) <5% FT (0.4 - 0.8) Verluma (0.0 - 0.4) |
| Tc-99m Sulesomab (LeukoScan) |
ITLC |
ITLC-SG 1 x 9 cm (Spot with 1:150 dilution of prep) |
Acetone |
FT (1.0) LeukoScan (0.0) |
| Tl-201 Chloride |
ITLC |
ITLC-SG |
Acetone |
Tl+3 (1.0) Tl+1 (0.0) NMT 2% Tl-200, 0.3% Pb-203, 2.7% Tl-202 |
| Cr-51 Sodium Chromate |
ITLC |
ITLC-SG |
n-butanol: 1N HCl (1:1) |
Cr+6 (0.9) Cr+3 (0.2) |
| Xe-133 gas |
Radiometric |
81 and 31 kev (all others <5%) | ||
| Co-57 Cyanocobalamin |
ITLC |
ITLC-SG |
10% NaCl |
Co ion (1.0) Cyanocobal (0.2 - 0.5) |
| I-125 Albumin |
ITLC |
ITLC-SG |
MeOH |
Iodide (1.0) I-125 Albumin (0.1) |
| I-125 Sodium Iothalamate |
ITLC |
ITLC-SG |
Benzene: Glacial Acetic Acid: Water (2:2:1 v/v/v). Discard upper phase |
Iodide (1.0) Iothalamate (0.2) |
| Radiopharmaceutical | Method | Support Media | Solvent | Cpd (Rf) |
| I-131 Sodium Iodide (Capsule) |
Radiometric |
19 of 20 capsules in a lot must contain 95.5 - 103.5% of mean capsule activity | ||
| I-131 Sodium Iodide (Solution) |
ITLC |
ITLC-SG |
n-Butanol: 3N NH4OH (1:1) |
Iodide (1.0) Triiodide (0.4) Iodate (0.0) |
| I-131 MIBG (Iobenguane) |
SepPak |
C-18 Cartridge |
Water, Tetrahydrofurantoin: 0.1M Na dihydrogen phosphate (25:75 v/v) - Twice |
Inorganic impurities (water) Iobenguane (Tetra: Phosph) |
| I-123 Sodium Iodide (Capsule) |
Radiometric |
At calibration-NLT 99.5% At expiration-NLT 98.28% |
||
| Ga-67 Citrate |
ITLC |
Whatman #1 |
Pyridine: EtOH: Water (1:2:4) adjust pH 6 with 3N HCl |
Ga citrate (0.9) Gallate (0.6) Ga hydroxide (0.0) At calibration and expiration-NLT 99.89% |
| In-111 DTPA |
ITLC |
Whatman #1 |
MeOH-85% |
DTPA (0.8 - 1.0) Hydrolyzed In (0.0) At calibration-NLT 99.0% |
| In-111 Oxyquinoline (Oxine) |
At calibration-NMT 1mCi In-114m/mCi In-111 At expiration-NMT 0.25% In-114m |
|||
| In-111 Pentetreotide Octreoscan |
SepPak |
C18 Cartridge |
Water MeOH |
Unbound In-111 (Water) Octreoscan (MeOH) Non-elutables (SepPak) |
| In-111 Capromab Pendetide (ProstaScint) |
ITLC |
ITLC-SG 1 x 8 cm (Spot with Prostascint/0.05M DTPA mixture) |
Saline |
In-111 as DTPA (1.0) Prostascint (0.0) |
| In-111 Satumomab Pendetide (OncoScint CR/OV) |
ITLC |
ITLC-SG 1 x 8 cm (Spot with Oncoscint/0.05M DTPA mixture) |
Saline |
In-111 as DTPA (1.0) Oncoscint CR/OV (0.0) |
| F-18 FDG (Fludeoxyglucose) |
ITLC |
ITLC-SG |
Acetonitrile: Water (95:5) |
FDG (0.4) |
| P-32 Sodium Phosphate Solution |
ITLC |
ITLC-SG (Spot with P-32/10% v/v Phosphoric acid (1:20) |
n-Amyl Alcohol: Formic acid: Water (8:1:4) |
Phosphates reduced by phosphoric acid (0.6) Impurities-Other peaks |
| Radiopharmaceutical | Method | Support Media | Solvent | Cpd (Rf) |
| P-32 Chromic Phosphate |
ITLC |
Whatman #1 |
Deionized Water |
Chromic Phosphate (0.0) |
| Sr-89 Chloride (Metastron) |
||||
| Sm-153 Lexidronam (Quadramet) |
||||
| Rb-82 Chloride (CardioGen 82) |
Radiometric |
NMT 0.02 μCi Sr-82 and NMT 0.2 μCi Sr-85 per mCi 82RbCl. NMT 1 μgm tin per ml of eluate |
||
| In-111 or Y-90 Ibritumomab tiuxetan (Zevalin) |
ITLC |
ITLC-SG |
0.9% NaCl |
In-111 or Y-90 Zevalin (0.0) In-111 or Y-90 Chloride (1.0) |
| Rf | Reference factor |
|---|---|
| FT | Free Tc-99m |
| HR | Hydrolyzed-Reduced Tec-99m |
| EtOH | Ethyl alcohol |
| 1o | Primary compound (Compound of interest) |
| 2o | Secondary compound (Radiochemical impurity) |
| NMT | Not More Than |
Return to the Beginning of the Document
Return to the Table of Content